The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK

被引：0

作者：

Thompson, G. ^{[1
]}

Schroeder, M. ^{[1
]}

Neslusan, C. ^{[2
]}

Willis, M. ^{[3
]}

Johansen, P. ^{[3
]}

Teschemaker, A. ^{[2
]}

机构：

[1] Janssen UK, High Wycombe, Bucks, England

[2] Janssen Global Serv LLC, Raritan, NJ USA

[3] Swedish Inst Hlth Econ, Lund, Sweden

来源：

DIABETOLOGIA | 2014年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

817

引用

页码：S330 / S330

页数：1

共 50 条

[31] Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus
Ektare, Varun U.
Lopez, Janice M. S.
Martin, Silas C.
Patel, Dipen A.
Rupnow, Marcia F. T.
Botteman, Marc F.
AMERICAN JOURNAL OF MANAGED CARE, 2014, 20 (10): : S204 - S215
[32] Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)
Gavin, James R., III
Davies, Melanie J.
Davies, Michael
Vija-Purkar, Ujjwala
Alba, Maria
DIABETES, 2014, 63 : A285 - A285
[33] Comparison of Treatment With Sitagliptin (SITA) or Sulfonylurea (SU) in Patients With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Insufficiency
Engel, Samuel S.
Xu, Lei
Golm, Gregory T.
O'Neill, Edward A.
Kaufman, Keith D.
Goldstein, Barry J.
DIABETES, 2013, 62 : A139 - A139
[34] Characteristics of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Therapy with Canagliflozin
Martin, Silas C.
Henk, Henry J.
Chow, Wing
DIABETES, 2014, 63 : A307 - A307
[35] TIME UNTIL INSULIN INITIATION FOR CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN DUAL AND TRIPLE THERAPY FOR TYPE 2 DIABETES MELLITUS (T2DM) IN IRELAND
Bacon, T.
Willis, M.
Johansen, P.
Neslusan, C.
VALUE IN HEALTH, 2015, 18 (03) : A55 - A55
[36] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) 10MG AND EMPAGLIFLOZIN (EMPA) 25MG IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS MONOTHERAPY IN THE UNITED KINGDOM
Schroeder, M.
Johansen, P.
Willis, M.
Neslusan, C.
VALUE IN HEALTH, 2015, 18 (07) : A607 - A607
[37] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS INSULIN-SECRETAGOGUES (SULPHONYLUREAS) OR INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) AS AN ADD-ON TO METFORMIN IN IRELAND
Bacon, T.
Willis, M.
Johansen, P.
Neslusan, C.
Nuhoho, S.
Worbes-Cerezo, M.
VALUE IN HEALTH, 2014, 17 (07) : A346 - A346
[38] BUDGET IMPACT ANALYSIS OF UTILIZING CANAGLIFLOZIN (CANA) FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN AN UNITED STATES HEALTH PLAN
Vo, L.
Martin, S.
VALUE IN HEALTH, 2014, 17 (03) : A243 - A243
[39] Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects With Type 2 Diabetes Mellitus (T2DM) Over 52 Weeks
Stenloef, Kaj
Cefalu, William T.
Kim, Kyoung-Ah
Jodar, Esteban
Alba, Maria
Edwards, Robert
Tong, Cindy
Canovatchel, William
Meininger, Gary
DIABETES, 2013, 62 : A303 - A303
[40] Effects of Canagliflozin (CANA) on Biomarkers of Cardiovascular (CV) Stress in Older Patients with Type 2 Diabetes Mellitus (T2DM)
Januzzi, James L.
Butler, Javed
Jarolim, Petr
Sattar, Naveed
Vijapurkar, Ujjwala
Merton, Katherine W.
Ren, Jimmy
Canovatchel, William
Desai, Mehul
Davies, Michael J.
DIABETES, 2017, 66 : LB40 - LB40

← 1 2 3 4 5 →